Olympus (FRA:OLY1) Research & Development: €0 Mil (TTM As of Mar. 2026)


FRA:OLY1 Olympus Corp FRA:OLY1
82 GF Score
Price €9.06
GF Value €13.95
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Olympus Research & Development?

Olympus FRA:OLY1 +3.45% 82 Research & Development is €0 Mil as of Mar. 2026. GuruFocus rates FRA:OLY1 with a GF Score™ of 82/100 and a GF Value™ of €13.95 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Olympus's Research & Development for the three months ended in Mar. 2026 was €0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €0 Mil.

Olympus  (FRA:OLY1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Olympus Research & Development Related Terms

Olympus Research & Development Historical Data

* Premium members only.

The historical data trend for Olympus's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Olympus Research & Development Chart

Olympus Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Olympus Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:OLY1
82GF Score
Olympus Corp FRA:OLY1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Olympus Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0 Mil mean?
Olympus (FRA:OLY1) has a Research & Development of €0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Olympus and its competitors.
Is Olympus' Research & Development too high?
Olympus' current Research & Development is €0 Mil. Overall, Olympus has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Olympus' Research & Development compare to ABT and SYK?
Olympus' Research & Development of €0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Olympus and its competitors. Olympus's current Research & Development is €0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olympus stock overvalued right now?
Based on GuruFocus' analysis, Olympus (FRA:OLY1) is currently considered Significantly Undervalued. The stock's GF Value™ is €13.95, compared to a current price of €9.06 — trading 35.1% below its estimated fair value. The current Research & Development is €0 Mil. Olympus' overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Olympus (FRA:OLY1), the current Research & Development is €0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Olympus (FRA:OLY1) Overvalued in 2026?

Based on GuruFocus' analysis, Olympus stock appears to be undervalued. The current stock price of €9.06 is trading 35.1% below its estimated GF Value™ of €13.95. GuruFocus considers Olympus to be Significantly Undervalued.

Key valuation signals for FRA:OLY1:

  • Research & Development: €0 Mil
  • GF Value™: €13.95 vs. price of €9.06 (35.1% below fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the FRA:OLY1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Olympus Business Description

Address 2951 Ishikawacho, Hachioji, JPN, 192-8507
Olympus is a medical-device maker with a leading position in the endoscope market and a diversified global revenue stream. Originally founded in 1919 in Japan as a microscope and camera maker, Olympus has gradually pivoted into endoscopic and therapeutic solutions. As of March 2025, more than 60% of its revenue comes from endoscopic solutions. In addition, North America is the biggest revenue contributor by region, accounting for 38% of its total revenue.
82GF Score

Get the complete analysis for FRA:OLY1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.06
Price
€13.95
GF Value